29 June 2020 in Proceedings of the National Academy of Sciences
Significance: The Notch signaling cascade is deregulated by oncogenic lesions in human cancers and has therefore become an attractive therapeutic target. Inhibitory monoclonal antibodies and small-molecule γ-secretase inhibitors have been developed to target the pathway at the most proximal point of the cascade. Major hurdles to the therapeutic application of these Notch inhibitors have been prevalent dose-limiting toxicities in the intestine. Here we report identification and preclinical validation of a small molecule (CB-103) that inhibits the pathway at the level of the Notch transcription complex without causing intestinal toxicity. Its properties and mechanism of action provide CB-103 with a more favorable therapeutic index than other types of Notch targeting agents, a feature that is currently being tested in cancer patients.